Investigational Drug Details
| Drug ID: | D410 |
| Drug Name: | Fusidic acid |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB02703 |
| DrugBank Description: | An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections. |
| PubChem ID: | 3000226 |
| CasNo: | 6990-06-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C |
| Structure: |
|
| InChiKey: | IECPWNUMDGFDKC-MZJAQBGESA-N |
| Molecular Weight: | 516.7092 |
| DrugBank Targets: | Elongation factor G; Chloramphenicol acetyltransferase; Chloramphenicol acetyltransferase 3 |
| DrugBank MoA: | Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes. |
| DrugBank Pharmacology: | Fusidic acid is a bacteriostatic antibiotic and helps prevent bacterial growth while the immune system clears the infection. |
| DrugBank Indication: | For the treatment of bacterial infections. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|